Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy
2019
Abstrakt
We investigate for the first time the prognostic impact of CTPC by NGF in blood of 137 newly diagnosed MM patients after active treatment outside clinical trial, in parallelto BM MRD and serum immunofixation (sIF). Overall, a total of 328 samples were analyzed: 274 paired BM and blood samples,plus 54 follow-up blood specimens.
Following the EuroFlow-NGF MM MRD approach, 4a median (range) of 6 mL (3-14 mL) of blood and 1.8 mL (0.3-5 mL) of BM sample were lysed to (systematically) obtain 107cells per sample. In parallel, sIF wasmeasured by the HYDRAGEL kit (HYDRASYS system, Sebia,Barcelona, Spain).
Statistical significance was set at P values 0,5.